Aktis Oncology (AKTS) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OPKO Health is the larger company by market cap ($1.02 billion vs $965.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | OPK |
|---|---|---|
| Share price | $17.36 | $1.37 |
| Market cap | $965.55M | $1.02B |
| 1-day change | -3.56% | -1.44% |
| YTD return | — | +10.32% |
| 1-year return | — | -9.74% |
| 5-year return | — | -62.63% |
| EPS (TTM) | $-1.70 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $1.75 |
| 52-week low | $14.72 | $0.98 |
| Distance from 52-week high | -49.22% | -21.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +103.86% | +219.71% |
| Average volume | 364.04K | 3.35M |
| Shares outstanding | 53.75M | 746.33M |
| Employees | 79 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
AKTS vs OPK FAQ
Which is bigger, Aktis Oncology or OPKO Health?
OPKO Health (OPK) is larger, with a market capitalization of $1.02B compared with $965.55M for Aktis Oncology (AKTS).
Are Aktis Oncology and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.